NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

NBY

Novabay Pharmaceuticals Inc

Apr 17 • 04:00PM ET

0.6000

Dollar change +0.0120
Percentage change 2.04	%

Healthcare • Biotechnology • USA • AMEX

Peers: OMER CLSD TTOO CNTX CLRB CTXR PAVM SLS INTZ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.16	Insider Own	0.01%	Shs Outstand	5.82M	Perf Week	22.45%
Market Cap	3.49M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	5.82M	Perf Month	-0.41%
Income	-8.60M	PEG	-	EPS next Q	-	Inst Own	20.41%	Short Float	0.56%	Perf Quarter	-14.25%
Sales	9.78M	P/S	0.36	EPS this Y	-	Inst Trans	0.68%	Short Ratio	0.32	Perf Half Y	-1.15%
Book/sh	-0.03	P/B	-	EPS next Y	-	ROA	-26.25%	Short Interest	0.03M	Perf Year	-78.44%
Cash/sh	0.07	P/C	8.12	EPS next 5Y	-	ROE	-452.75%	52W Range	0.36 - 9.08	Perf YTD	-0.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	66.43%	ROI	-1481.90%	52W High	-93.39%	Beta	0.37
Dividend TTM	-	Quick Ratio	0.41	Sales past 5Y	12.11%	Gross Margin	66.26%	52W Low	66.16%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	0.68	EPS Y/Y TTM	93.83%	Oper. Margin	-50.85%	RSI (14)	55.04	Volatility	9.96% 6.78%
Employees	14	Debt/Eq	-	Sales Y/Y TTM	-33.58%	Profit Margin	-87.87%	Recom	1.00	Target Price	0.85
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	99.05%	Payout	-	Rel Volume	0.38	Prev Close	0.59
Sales Surprise	-7.64%	EPS Surprise	2054.17%	Sales Q/Q	-38.05%	Earnings	Apr 02 BMO	Avg Volume	101.10K	Price	0.60
SMA20	5.74%	SMA50	-0.92%	SMA200	-18.67%	Trades		Volume	38,375	Change	2.04%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-19	Initiated	Ladenburg Thalmann	Buy	$1.10
Jul-06-18	Reiterated	H.C. Wainwright	Buy	$4
Nov-15-17	Reiterated	Laidlaw	Buy	$10 → $8
Jun-05-17	Initiated	ROTH Capital	Buy	$5.50
Mar-27-17	Initiated	Laidlaw	Buy	$10
Feb-06-17	Initiated	Rodman & Renshaw	Buy	$6
Mar-07-16	Downgrade	Maxim Group	Buy → Hold
Dec-14-15	Reiterated	Maxim Group	Buy	$1 → $0.23
Apr-30-15	Resumed	Maxim Group	Buy	$2
Mar-06-13	Initiated	Ascendiant Capital Markets	Strong Buy	$2.25
Jan-03-08	Initiated	Dawson James	Speculative Buy	$8

Show Previous Ratings

Mar-07-25 06:50AM	NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders (Business Wire)
Jan-23-25 08:00AM	NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal (Business Wire) -12.33%
Dec-25-24 12:00PM	NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why (Zacks)
Dec-19-24 06:50AM	NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders (Business Wire)
Dec-09-24 06:50AM	NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting (Business Wire)
04:05PM	Loading…
Nov-22-24 04:05PM	NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 (Business Wire) -5.39% -8.66%
Nov-15-24 08:00AM	Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals Proposals to Authorize the Sale of its Avenova Brand (Business Wire)
Nov-07-24 04:05PM	NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-06-24 04:05PM	NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price (Business Wire) -5.30%
Oct-29-24 08:00AM	NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC (Business Wire) +18.24%
Sep-20-24 08:30AM	Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals (PR Newswire) +48.92%
08:00AM	NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets (Business Wire)
Aug-13-24 04:05PM	NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results (Business Wire) +15.33%
Aug-01-24 06:50AM	NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024 (Business Wire) -10.29%
Jul-30-24 06:50AM	NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales (Business Wire)
04:05PM	Loading…
Jul-29-24 04:05PM	NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option (Business Wire) -5.74%
Jul-26-24 08:30AM	NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering (Business Wire) -63.91%
Jul-16-24 06:50AM	NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day (Business Wire)
Jul-11-24 06:50AM	NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million (Business Wire) +5.19%
Jul-01-24 06:50AM	NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities (Business Wire)
Jun-28-24 06:50AM	NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions (Business Wire) -9.43%
Jun-07-24 06:50AM	NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American (Business Wire) -9.06%
May-29-24 05:22PM	NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates (Business Wire) +15.67% -36.11%
May-13-24 11:09AM	NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:30AM	NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms (Business Wire)
May-09-24 04:05PM	NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results (Business Wire) -9.97%
May-07-24 08:00AM	NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon (Business Wire)
May-03-24 06:50AM	NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024 (Business Wire) +5.44%
Apr-22-24 06:57AM	NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales (Business Wire) -12.01%
Apr-19-24 06:00PM	NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity (Business Wire)
06:59AM	Loading…
Apr-17-24 06:59AM	NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses (Business Wire)
Mar-27-24 11:28AM	NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript (Insider Monkey) -19.99%
09:57AM	Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-26-24 04:05PM	NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results (Business Wire) +7.83%
Mar-25-24 06:38PM	NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024 (Business Wire) -5.36%
Mar-14-24 08:00AM	NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023 (Business Wire)
Mar-13-24 07:00AM	NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals (GlobeNewswire)
Jan-30-24 09:00AM	NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales (Business Wire) -9.34%
Jan-09-24 09:15AM	NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonomas Extensive Distributor Network (ACCESSWIRE)
Dec-06-23 06:50AM	NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes (Business Wire)
Nov-12-23 08:33AM	NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results (Business Wire) +5.73% -8.23%
Nov-02-23 06:50AM	NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023 (Business Wire)
Oct-11-23 08:00AM	NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs (Business Wire)
Oct-02-23 06:50AM	NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference (Business Wire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-14-23 08:00AM	NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft (Business Wire)
Sep-11-23 08:00AM	NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft (Business Wire) +11.45%
Aug-15-23 06:31AM	NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:44AM	Q2 2023 NovaBay Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.14%
Aug-10-23 04:05PM	NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results (Business Wire) +6.10%
Aug-08-23 04:05PM	NovaBay Pharmaceuticals to Hold Second Quarter 2023 Conference Call on August 10, 2023 (Business Wire)
Jul-14-23 08:30AM	NovaBay Pharmaceuticals Reports Record Avenova Sales Day (Business Wire)
Jul-10-23 06:50AM	NovaBay Pharmaceuticals Announces Exclusive Amazon Prime Day 2023 Promotions on All Avenova-Branded Products (Business Wire) +5.18%
Jun-28-23 06:50AM	NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Educational Programs and Avenova Product Promotions (Business Wire)
Jun-20-23 06:50AM	NovaBay Pharmaceuticals to Showcase its Full Line of Avenova Eyecare Products at the 126th Annual American Optometric Association Congress (Business Wire) +8.76%
Jun-12-23 06:50AM	NovaBay Pharmaceuticals Announces DERMAdoctors KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to be Featured on QVC at a Special Price (Business Wire) +5.87%
May-30-23 07:00AM	Presenting on the Emerging Growth Conference on May 31 Register Now (GlobeNewswire)
May-29-23 01:52PM	NovaBay Pharmaceuticals looking to grow its three verticals of eye, skin, and wound care in 2023 (News Direct)
May-24-23 06:50AM	NovaBay Pharmaceuticals to Present at the Emerging Growth Virtual Conference on May 31, 2023 (Business Wire) -6.38%
May-11-23 04:05PM	NovaBay Pharmaceuticals Reports First Quarter 2023 Financial Results (Business Wire)
May-05-23 06:50AM	PhaseOne Health Collaborates with Nonprofit Humanitarian Organization to Supply NovaBay Pharmaceuticals Phase One® Skin and Wound Cleanser to Ukraine (Business Wire)
May-04-23 06:50AM	NovaBay Pharmaceuticals to Hold First Quarter 2023 Conference Call on May 11, 2023 (Business Wire)
May-01-23 06:50AM	NovaBay Pharmaceuticals Fulfills $1 Million Order for NeutroPhase® Skin and Wound Cleanser for China Pioneer Pharma Holdings (Business Wire)
Apr-27-23 04:47PM	NovaBay Pharmaceuticals Announces $3.0 Million Convertible Note Financing (Business Wire) -16.67%
Apr-21-23 06:50AM	NovaBay Pharmaceuticals Launches DERMAdoctors New Comfort + Joy Psoriasis Therapeutic Moisturizing Cream on the QVC® Network (Business Wire)
Mar-30-23 04:06PM	NovaBay Pharmaceuticals Reports 2022 Fourth Quarter and Full Year Financial Results (Business Wire)
Mar-23-23 06:50AM	NovaBay Pharmaceuticals to Hold 2022 Fourth Quarter and Full Year Conference Call on March 30, 2023 (Business Wire)
Mar-14-23 06:50AM	Eyeganics Organic Tears, the Only USDA-Certified Organic Lubricant Eye Drop, Now Available through NovaBay Pharmaceuticals Avenova.com and Physician-Dispensed Channel (Business Wire)
Mar-07-23 06:50AM	NovaBay Pharmaceuticals Launches Avenova® Eye Health Support, a New Antioxidant-Rich Oral Supplement to Comfort Dry Eyes and Promote Overall Eye Health (Business Wire) -6.02%
Feb-06-23 06:50AM	NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctors Eczema Treatment on Two QVC® Shows on February 7 (Business Wire)
Jan-31-23 06:50AM	NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 (Business Wire)
Jan-17-23 06:50AM	PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market (Business Wire)
Nov-29-22 06:50AM	NovaBay Pharmaceuticals Announces the Launch of DERMAdoctors TikTok Store in China and Expands Online Marketing in the U.S. and China (Business Wire)
Nov-17-22 06:50AM	NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC® Network With DERMAdoctors Eczema Balm (Business Wire) -9.32%
Nov-14-22 04:05PM	NovaBay Pharmaceuticals Reports Third Quarter 2022 Financial Results (Business Wire)
04:02PM	NovaBay Pharmaceuticals Announces 1-for-35 Reverse Stock Split (Business Wire)
Nov-09-22 04:05PM	NovaBay Pharmaceuticals to Hold Third Quarter 2022 Conference Call on November 14 (Business Wire) -9.51%
Oct-26-22 06:50AM	NovaBay Pharmaceuticals Announces Expansion of DERMAdoctor Picture Porefect Collection with Launch of 15% Niacinamide Pore Minimizing Serum (Business Wire) +11.89%
Oct-19-22 06:50AM	NovaBay Pharmaceuticals to Present at the LD Micro Main Event XV (Business Wire)
Oct-18-22 06:50AM	NovaBay Pharmaceuticals Announces Significant Orders for DERMAdoctors Top-Selling Kakadu C Anti-Aging Serum ahead of the Holiday Season (Business Wire)
Oct-10-22 06:50AM	NovaBay Pharmaceuticals Avenova® and DERMAdoctor® Products to be Featured During the October 11-12 Amazon Prime Early Access Sale (Business Wire)
Oct-07-22 04:05PM	NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Low Share Price (Business Wire) -6.27%
Sep-23-22 06:50AM	NovaBay Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference (Business Wire) -8.86%
Sep-22-22 04:05PM	NovaBay Pharmaceuticals CEO Issues Letter to Stockholders (Business Wire)
Sep-16-22 08:35AM	Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing (GlobeNewswire) -5.53%
Sep-13-22 06:50AM	NovaBay Pharmaceuticals to Present at the Virtual Life Sciences Investor Forum (Business Wire)
Sep-12-22 08:35AM	Life Sciences Virtual Investor Conference Agenda Announced for September 15th (GlobeNewswire)
06:50AM	NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Showcase DERMAdoctors Eczema Balm on Return QVC® Appearance (Business Wire)
Sep-09-22 08:00AM	NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million (Business Wire) -13.03%
Aug-11-22 04:30PM	Edited Transcript of NBY.A earnings conference call or presentation 11-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents) -8.23%
04:05PM	NovaBay Pharmaceuticals Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-04-22 06:50AM	NovaBay Pharmaceuticals to Hold Second Quarter 2022 Conference Call on August 11 (Business Wire)
Jul-28-22 06:50AM	NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova® Lid and Lash Spray for Lash Extensions (Business Wire)
Jul-21-22 06:50AM	NovaBay Pharmaceuticals DERMAdoctor Products Now Available at Target.com and Urbanoutfitters.com (Business Wire)
Jul-15-22 06:50AM	NovaBay Pharmaceuticals Reports Record Avenova® Sales During Amazons Prime Day Event (Business Wire)
Jul-07-22 06:50AM	NovaBay Pharmaceuticals DERMAdoctor Products to be Featured at Leading B2B Beauty Trade Show Cosmoprof North America (Business Wire) +6.90%
May-12-22 04:05PM	NovaBay Pharmaceuticals Reports First Quarter 2022 Financial Results (Business Wire) +5.21%
May-09-22 06:50AM	NovaBay Pharmaceuticals Expands Top-Selling DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-Aging Formulations (Business Wire) -11.60%
May-05-22 06:50AM	NovaBay Pharmaceuticals to Hold First Quarter 2022 Conference Call on May 12 (Business Wire)

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
POPLAR POINT CAPITAL PARTNERS	10% Owner	Apr 03 '25	Buy	0.56	22,976	12,929	1,015,462	Apr 15 12:50 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Apr 04 '25	Buy	0.52	4,538	2,367	1,020,000	Apr 15 12:50 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Apr 02 '25	Buy	0.58	917	532	992,486	Apr 15 12:50 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Apr 08 '25	Buy	0.47	300	140	1,020,300	Apr 15 12:50 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 28 '25	Buy	0.61	49,400	30,253	950,000	Apr 15 12:46 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 31 '25	Buy	0.59	21,654	12,776	971,654	Apr 15 12:46 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 27 '25	Buy	0.61	19,104	11,745	900,600	Apr 15 12:46 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Apr 01 '25	Buy	0.58	19,915	11,650	991,569	Apr 15 12:46 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 26 '25	Buy	0.61	13,292	8,095	881,496	Apr 15 12:46 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 25 '25	Buy	0.61	22,635	13,807	868,204	Apr 15 12:40 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 18 '25	Buy	0.63	14,000	8,820	832,277	Apr 15 12:40 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 21 '25	Buy	0.60	6,372	3,855	845,469	Apr 15 12:40 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 20 '25	Buy	0.61	5,320	3,271	839,097	Apr 15 12:40 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 19 '25	Buy	0.60	1,500	904	833,777	Apr 15 12:40 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 24 '25	Buy	0.60	100	60	845,569	Apr 15 12:40 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 14 '25	Buy	0.63	25,511	16,072	808,277	Apr 15 12:30 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 10 '25	Buy	0.58	14,645	8,494	768,747	Apr 15 12:30 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 12 '25	Buy	0.62	11,837	7,370	782,732	Apr 15 12:30 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 18 '25	Buy	0.63	10,000	6,300	818,277	Apr 15 12:30 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 11 '25	Buy	0.58	2,148	1,246	770,895	Apr 15 12:30 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 13 '25	Buy	0.64	34	22	782,766	Apr 15 12:30 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 25 '25	Buy	0.62	25,033	15,518	730,205	Apr 15 12:22 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 28 '25	Buy	0.60	13,108	7,891	750,000	Apr 15 12:22 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 26 '25	Buy	0.61	6,302	3,844	736,507	Apr 15 12:22 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 04 '25	Buy	0.58	4,000	2,314	754,000	Apr 15 12:22 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 27 '25	Buy	0.61	385	235	736,892	Apr 15 12:22 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Mar 07 '25	Buy	0.55	102	56	754,102	Apr 15 12:22 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 19 '25	Buy	0.67	49,664	33,349	702,886	Apr 15 12:18 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 04 '25	Buy	0.64	26,718	16,966	650,000	Apr 15 12:18 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 18 '25	Buy	0.66	3,222	2,127	653,222	Apr 15 12:18 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 03 '25	Buy	0.64	2,597	1,649	623,282	Apr 15 12:18 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 20 '25	Buy	0.63	1,836	1,157	704,722	Apr 15 12:18 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Feb 24 '25	Buy	0.62	450	279	705,172	Apr 15 12:18 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Jan 31 '25	Buy	0.65	70,685	45,825	620,685	Apr 15 12:11 PM
POPLAR POINT CAPITAL PARTNERS	10% Owner	Jan 27 '25	Buy	0.69	31,703	21,875	550,000	Apr 15 12:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NBY

Novabay Pharmaceuticals Inc

Upgrade your FINVIZ experience